Abeona books $13.5M from gene therapy launch as one batch fails release testing

Abeona Therapeutics said on 9 November that its recessive dystrophic epidermolysis bullosa therapy, Zevaskyn (prademagene zamikeracel), generated $13.5 million in net revenue in the third quarter of 2026. The company described this as an 18% increase. The summary available to CompePharma does not state which period that growth is measured against, nor how many treatments were completed within the quarter.

Fifteen patients have now been treated since the product reached the market, and the company's QTC network has grown to eight sites. Together, the figures give an early indication of how quickly a treatment that depends on specialised centres is being taken up.

One treatment did not count towards revenue. Abeona said it held back recognition after a manufactured batch failed an identity test required for release. The information available does not explain the cause or say what happened to the patient concerned. In general, products made from a patient's own cells cannot easily be replaced if a batch fails, so a release failure can delay treatment and defer revenue.

On reimbursement, the US Centers for Medicare & Medicaid Services granted Zevaskyn New Technology Add-On Payment (NTAP) status, effective 1 October 2026. As context, NTAP is a Medicare mechanism that can give hospitals additional payment for expensive new technologies used in inpatient care. How much it helps will depend on how individual sites bill.

Abeona also disclosed that it has acquired ABO-801, a programme for eosinophilic oesophagitis, and has raised $30 million through a PIPE (private investment in public equity). No further terms of either transaction were available.